Association of aspirin use with major bleeding in patients with and without diabetes

JAMA

Volumn 307, Issue 21, 2012, Pages 2286-2294

  De Berardis, Giorgia ^a   Lucisano, Giuseppe ^a   D'Ettorre, Antonio ^a   Pellegrini, Fabio ^a,b   Lepore, Vito ^a,c   Tognoni, Gianni ^a   Nicolucci, Antonio ^a  

^a Consorzio Mario Negri Sud ^*  (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; ITALY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPENSITY SCORE; SEX DIFFERENCE;

EID: 84861864488     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.5034     Document Type: Article

References (41)

1. Pignone M, Alberts MJ, Colwell JA, et al American Diabetes Association; American Heart Association; American College of Cardiology Foundation. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care. 2010;33(6):1395-1402.
2. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(6):396-404.
3. Baigent C, Blackwell L, Collins R, et al Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-1860.
4. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23(1):163-173. (Pubitemid 46201599)
5. McQuaid KR, Laine L. Systematic review and metaanalysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119(8):624-638. (Pubitemid 44128438)
6. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998;280(22):1930-1935. (Pubitemid 28559811)
7. Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet. 2008;372(9656):2152-2161.
8. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373-2383. (Pubitemid 41713749)
9. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index With DDDs. Norway, Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2003.
10. US Centers for Disease Control and Prevention. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). http://www.cdc.gov/nchs/icd/icd9cm.htm. Accessibility verified May 14, 2012.
11. Macchia A, Romero M, D'Ettorre A, Mariani J, Tognoni G. Temporal trends of the gaps in postmyocardial infarction secondary prevention strategies of co-morbid and elderly populations vs younger counterparts: an analysis of three successive cohorts between 2003 and 2008. Eur Heart J. 2012;33(4):515-522.
12. Monte S, Macchia A, Romero M, D'Ettorre A, Giuliani R, Tognoni G. Antidepressants and cardiovascular outcomes in patients without known cardiovascular risk. Eur J Clin Pharmacol. 2009;65(11):1131-1138.
13. Macchia A, Monte S, Pellegrini F, et al. Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. Eur J Clin Pharmacol. 2008;64(6):627-634.
14. Macchia A, Monte S, Romero M, D'Ettorre A, Tognoni G. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur J Heart Fail. 2007;9(9):942-948. (Pubitemid 47332320)
15. De Berardis G, D'Ettorre A, Graziano G, et al; for the DADA(Diabetes Administrative Data Analysis) Study Group. The burden of hospitalization related to diabetes mellitus: a population-based study. Nutr Metab Cardiovasc Dis. doi:10.1016/j.numecd.2010.10.016.
16. Lepore V, D'Ettorre A, Valerio M, et al. From pharmacoepidemiology to the epidemiology of delivered care [in Italian]. Ital J Clin Pharm. 2002;16(2):102-107. (Pubitemid 34951588)
17. Winkler WE. Comparative analysis of record linkage decision rules [year: 1992; pages: 829-834]. http://www.amstat.org/sections/srms/proceedings/. Accessibility verified May 11, 2012.
18. Italian Republic. Determination of the Italian Medicines Agency of March 20, 2008 [in Italian]. Official Gazette of the Italian Republic. General Series No. 76; March 31, 2008.
19. Rahme E, Nedjar H, Bizzi A, Morin S. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study. Aliment Pharmacol Ther. 2007;26(10):1387-1398. (Pubitemid 350045614)
20. Yanovitzky I, Zanutto E, Hornik R. Estimating causal effects of public health education campaigns using propensity score methodology. Eval Program Plann. 2005;28:209-220. (Pubitemid 40393579)
21. Parsons LS. Reducing bias in a propensity score matched pair sample using greedy matching techniques. In: Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference. Cary, NC: SAS Institute; 2004.
22. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26(4):734-753. (Pubitemid 46206593)
23. García Rodríguez LA, Hernaíndez-Díaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001;52(5):563-571.
24. Bhatt DL, Scheiman J, Abraham NS, et al American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118(18):1894-1909.
25. Feigin VL, Rinkel GJ, Lawes CM, et al. Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies. Stroke. 2005;36(12):2773-2780.
26. Inagawa T. Risk factors for aneurysmal subarachnoid hemorrhage in patients in Izumo City, Japan. J Neurosurg. 2005;102(1):60-67. (Pubitemid 43186697)
27. Weil J, Langman MJ, Wainwright P, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut. 2000;46(1):27-31. (Pubitemid 30307672)
28. Pulcinelli FM, Biasucci LM, Riondino S, et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J. 2009;30(10):1279-1286.
29. De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009;339:b4531.
30. Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther. 2002;16(11):1945-1953.
31. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000;343(12):834-839.
32. Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160(14):2093-2099. (Pubitemid 30482713)
33. Russo P, Brutti C. Proton pump inhibitors and hospital discharge rates for gastrointestinal events in Italy: a national ecological study. Clin Ther. 2007;29(4):751-758. (Pubitemid 47018269)
34. Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med. 2011;171(3):218-225.
35. Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011;342:d2690.
36. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-944.
37. Siller-Matula JM, Jilma B, Schrör K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost. 2010;8(12):2624-2641.
38. Atar S, Cannon CP, Murphy SA, Rosanio S, Uretsky BF, Birnbaum Y. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis in Myocardial Infarction 16 (OPUS-TIMI 16) trial. Am Heart J. 2006;151:976.e1-e6.
39. Gulmez SE, Lassen AT, Aalykke C, et al. Do statins protect against upper gastrointestinal bleeding? Br J Clin Pharmacol. 2009;67(4):460-465.
40. Amarenco P, Bogousslavsky J, Callahan A III, et al Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559. (Pubitemid 44202151)
41. Hackam DG, Woodward M, Newby LK, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation. 2011;124(20):2233-2242.